Photo of Robert Maki

Robert Maki

  • PROFESSOR Pediatrics, Hematology/Oncology
  • PROFESSOR Medicine, Hematology and Medical Oncology
  • PROFESSOR Orthopaedics
Print ProfilePrint Profile


  • Medical Oncology

Clinical Focus


  • MD, Cornell University Medical College

  • PhD, Cornell Graduate School of Medical Sciences

  • Residency, Internal Medicine
    Brigham and Women's Hospital, Harvard Medical School

  • Fellowship, Medical Oncology
    Dana Farber Cancer Institute


    Dr. Robert Maki is Professor of Medicine, Pediatrics, and Orthopaedics, and the Steven Ravitch Chair in Pediatric Hematology-Onocology. He has published more than 100 articles on sarcoma treatment and basic science research, having worked on studies related to sarcoma since 1985. He treats adults and children with sarcomas (connective tissue cancers of bone, cartilage, muscle, fat and other soft tissue) and has an interest in translational research and the biology that leads to different types of sarcomas. 

    After his MD/PhD at Cornell Medical College in New York City, he was a resident at Brigham and Women's Hospital in Boston before a medical oncology fellowship at Dana-Farber, and was on staff at Dana-Farber before starting at Memorial Sloan-Kettering in 1999. In March, 2011 he moved to the Mount Sinai Medical Center to develop the effort in adult sarcoma therapy and research.

    Dr. Maki's efforts at Mount Sinai will be directed towards an increasingly integrative effort sarcoma biology and treatment of sarcomas. His group will conduct clinical trials in adults with sarcomas, and they will also conduct translational studies in sarcoma biology to identify the next possible targets for new drugs to treat sarcomas. 

    Dr. Maki is also the Director of Translational Oncology at the Sarcoma Alliance for Research through Collaboration (SARC).


  • 2013 - 2013
    Sarcoma Foundation of America Nobility in Science award

  • 2009 - 2011
    NCI-ASCO Clinical Investigator Team Leadership Award
    National Cancer Institute & American Society for Clinical Oncology


Developmental chemotherapeutics

Topics include:

  • Phase I-II-III clinical trials
  • Novel approaches, e.g. Bayesian designs, to accelerate drug development
  • Pharmacokinetics, pharmacodynamics, pharmacogenomics

Treatment of locally aggressive connective tissue tumors

Examples include:

  • Deep fibromatosis/desmoid tumor, superficial fibromatosis
  • Tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS)
  • Giant cell tumor of bone
  • Angiomyxoma, angiofibroma, angiomatoid fibrous histiocytoma
  • Giant hemangiomas

Treatment of sarcomas of soft tissue and bone

Examples include:

  • GIST (gastrointestinal stromal tumor)
  • Leiomyosarcoma
  • "UPS"/"MFH": undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma
  • Myxofibrosarcoma
  • Synovial sarcoma
  • Myxoid/round cell liposarcoma
  • Well differentiated/dedifferentiated liposarcoma
  • Pleomorphic liposarcoma
  • Angiosarcoma, Epithelioid hemangioendothelioma, and other vascular tumors
  • Spindle cell sarcoma not otherwise specified (NOS)
  • Uterine sarcomas (such as leiomyosarcoma, endometrial stromal sarcoma, high grade undifferentiated uterine sarcoma, carcinosarcoma or mixed mullerian tumor)
  • Osteogenic sarcoma (osteosarcoma)
  • Ewing sarcoma
  • Chondrosarcoma
  • Ewing sarcoma
  • Malignant peripheral nerve sheath tumor (MPNST)
  • Desmoplastic small round cell tumor (DSRCT)
  • Epithelioid sarcoma
  • PEComa (perivscular epithelial cell tumor)
  • Fibromyxoid sarcoma (Evans' tumor)
  • Phyllodes tumor of the breast
  • Chordoma
  • Small round blue cell tumors
  • Rhabdomyosarcoma
  • Lymph node sustentacular tumor (follicular dendritic cell tumor, interdigitating reticular cell tumor, Langerhans cell histiocytosis)
  • Alveolar soft part sarcoma (ASPS)
  • Clear cell sarcoma (of tendon sheath)

Translational sarcoma research

Examples include:

  • In vivo models of sarcomas
  • Genomic analysis of sarcoma subtypes
  • Identification of novel drug targets and therapeutics
  • Novel imaging modalities


Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Maki during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • Arcus Ventures (AV); Bayer; F. Hoffman-La Roche Ltd.; Foundation Medicine, Inc.; GlaxoSmithKline; ImClone Systems (Eli Lilly and Company)

Scientific Advisory Board:

  • Eisai Inc.; Gem Pharmaceuticals, LLC; TRACON Pharmaceuticals, Inc.; Taiho Pharmaceutical Co., Ltd.

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

  • Bayer

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • Eisai Inc.; Sarcoma Alliance for Research Through Collaboration (SARC)

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Icahn (East) Building Floor 1 Room TCI L1
1425 Madison Avenue
New York, NY 10029

Tel: 212-659-9695


Icahn (East) Building Floor Tisch Cancer Institute Room TCI-L1
1425 Madison Avenue
New York, NY 10029

Tel: 212-659-9695
Fax: 212-659-5599
Adult Patient Appointments

Ruttenberg Treatment Center
1470 Madison Avenue
New York, NY 10029

Tel: 212-241-6756
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
Insurance Plans
  • Aetna
  • Amerigroup
  • Beech Street
  • Blue Cross/ Blue Shield
  • Child Health Plus
  • Choice Care
  • Cigna
  • Coventry Health Care
  • Devon Health Services
  • GHI
  • HealthFirst/Medicaid HMO
  • HealthPlus, Inc.
  • Island Group
  • Magnacare
  • Medicaid
  • MetroPlus Health Plan
  • MultiPlan, Inc.
  • Neighborhood Health Providers, LLC
  • Oxford Health Plans
  • Pomco
  • Private Healthcare Systems (PHCS)
  • Travel Care Services
  • United Healthcare
Payment Methods
  • Master Card
  • Visa
  • Credit Card (Other)